Cost effectiveness of tumour necrosis factor-α inhibitors as first-line agents in rheumatoid arthritis

PharmacoEconomics

Volumn 24, Issue 12, 2006, Pages 1221-1232

  Spalding, James R ^a   Hay, Joel ^b  

^a ASTELLAS PHARMA GLOBAL DEVELOPMENT   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ETANERCEPT; INFLIXIMAB; METHOTREXATE; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ADULT; ARTICLE; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFECT; FEMALE; HUMAN; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; RHEUMATOID ARTHRITIS; SENSITIVITY ANALYSIS;

ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; COST-BENEFIT ANALYSIS; DISEASE PROGRESSION; DRUG COSTS; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; IMMUNOGLOBULIN G; METHOTREXATE; MIDDLE AGED; QUALITY-ADJUSTED LIFE YEARS; RECEPTORS, TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR-ALPHA;

EID: 33845453780     PISSN: 11707690     EISSN: 11707690     Source Type: Journal    
DOI: 10.2165/00019053-200624120-00006     Document Type: Article

References (51)

1. American College of Rheumatology. Guidelines for the management of rheumatoid arthritis: 2002 update. Arthritis Rheum 2002; 46 (2): 328-46
2. Hochberg M. Adult and juvenile rheumatoid arthritis: current epidemiologic concepts. Epidemiol Rev 1981; 3: 27-44
3. Cooper N. Economic burden of rheumatoid arthritis: a systematic review. Rheumatology 2000; 39: 28-33
4. Jobanputra P, Barton P, Bryan S, et al. The clinical effectiveness and cost-effectiveness of new drug treatments for rheumatoid arthritis: etanercept and infliximab. 2001 Sep 3 [online]. Available from URL: http://www.nice.org.uk/ page.aspx?o=29675 [Accessed 2006 Sep 6]
5. Arnett F, Edworthy S, Bloch D. The American Rheumatology Association 1987 revised criteria for classification or rheumatoid arthritis. Arthritis Rheum 1988 Mar; 31 (3): 315-24
6. MacGregor A, Schneider H, Rigby A, et al. Characterizing the quantitative genetic contribution to rheumatoid arthritis using data from twins. Arthritis Rheum 2000; 43: 30-7
7. Barton A, John S, Ollier W, et al. Association between rheumatoid arthritis and polymorphisms of tumor necrosis factor II, but not tumor necrosis factor in Caucasians. Arthritis Rheum 2001; 44: 61-5
8. Silman A. Epidemiology and rheumatic diseases. In: Maddison P, Isenburg D, Woo P, et al., editors. Oxford textbook of rheumatology. Oxford: Oxford University Press, 1998: 811-28
9. Maini R, Feldman M. Immunopathogenesis of rheumatoid arthritis. In: Maddison P, Isenburg D, Woo P, Glass D, editors. Oxford textbook of rheumatology. Oxford: Oxford University Press, 1998: 983-1004
10. Boyce E. Rheumatoid arthritis. In: Herfindal E, Gourley D, editors. Textbook of therapeutics: drug and disease management. 7th ed. Philadelphia (PA): Lippincott Williams & Wilkins, 2000: 641-66
11. Lotz M. Cytokines and their receptors. In: Koopman W, editor. Arthritis and allied conditions: a textbook of rheumatology. Philadelphia (PA): Lippincott Williams & Wilkins, 1996: 439-78
12. Van der Heide A, Jacobs J, Bijlsma W, et al. The effectiveness of early treatment with 'second-line' anti-rheumatic drugs. Ann Intern Med 1996; 124: 699-707
13. Piascik P. New antibody approved for the treatment of rheumatoid arthritis. J Am Pharm Assoc 2003; 43 (2): 327-8
14. Breedveld FC, Weisman MH, Kavanaugh AF, et al. The efficacy and safety of adalimumab (Humira.) plus methotrexate vs adalimumab alone or methotrexate alone in the early treatment of rheumatoid arthritis (RA): 1- and 2-year results of the PREMIER study [OP0013]. The Annual European Congress of Rheumatology; 2005 Jun 8-11; Vienna
15. St Clair W, van der Heijde D, Smolen J, et al. Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. Arthritis Rheum 2004; 50 (11): 3432-43
16. Genovese MC. Etanercept vs MTX in patients with early RA. Arthritis Rheum 2002; 46 (8): 1443-50
17. Cohen M, Keystone E, Weaver A. The role of biologics in optimizing RA treatment: a return to monotherapy? Rheumatology CME symposium; 2001 Nov 11-15; San Francisco (CA)
18. First DataBank's national drug data file plus (NDDF Plus) [electronic database]. San Bruno (CA): First DataBank, 2005 Oct
19. Express scripts drug trend 2002 report. Maryland Heights (MO): Express Scripts, Inc., 2003 Jun
20. Physicians' fee and coding guide. 16th ed. Duluth (GA): MAG Mutual Healthcare Solutions Inc., 2005
21. Jobanputra P, Barton P. The effectiveness of infliximab and etanercept for the treatment of rheumatoid arthritis: a systematic review and economic evaluation. Health Technol Assess 2002; 6 (21): 1-99
22. Healthcare Cost and Utilization Project (HCUP). 2003 inpatient data. Rockville (MD): Agency for Healthcare Research and Quality, 2003
23. Wolfe F, Michaud K. Lymphoma in rheumatoid arthritis: the effect of methotrexate and anti-tumor necrosis factor therapy in 18,572 patients. Arthritis Rheum 2004; 50 (6): 1740-51
24. Michaud K, Messer J, Choi HK, et al. Direct medical costs and their predictors in patients with rheumatoid arthritis: a three-year study of 7527 patients. Arthritis Rheum 2003; 48 (10): 2750-62
25. Yelin E, Wanke L. An assessment of annual and long-term direct costs of RA. Arthritis Rheum 1999; 42: 1209-18
26. Gold M, Russel L, Siegel J, et al. Cost-effectiveness in health and medicine. New York: Oxford Press, 1996
27. Kobelt G. Modeling the progression of rheumatoid arthritis: a two-country model to estimate costs and consequences of rheumatoid arthritis. Arthritis Rheum 2002; 46 (9): 2310-9
28. Kobelt G, Eberhardt K, Jonsson L, et al. Economic consequences of the progression of rheumatoid arthritis in Sweden. Arthritis Rheum 1999; 42 (2): 347-56
29. Kobelt G, Jonsson L, Young A, et al. The cost-effectiveness of infliximab (Remicade) in the treatment of rheumatoid arthritis in Sweden and the United Kingdom based on the attract study. Rheumatology 2003; 42: 326-35
30. Clark W, Jobanputra P, Barton P, et al. The clinical and cost-effectiveness of anakinra for the treatment of rheumatoid arthritis in adults. 2003 Jan [online]. Available from URL: http://www.nice.org.uk/page.aspx? o=65574 [Accessed 2006 Sep 6]
31. Breedveld FC, Weismann MH, Kavanaugh AF, et al. A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum 2006; 54 (1): 26-37
32. Hay J. Evaluation and review of pharmacoeconomic models. Expert Opin Pharmacother 2004; 5 (9): 1867-80
33. Keystone E, Kavanaugh A, Sharp J, et al. Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial. Arthritis Rheum 2004; 50 (5): 1400-11
34. Klareskog L, Heijde DVD, Jager JPD, et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet 2004; 363: 675-81
35. Lipsky PE, van der Heijde D, St Clair EW, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. N Engl J Med 2000; 343: 1594-602
36. van de Putte LBA, Atkins C, Malaise M, et al. Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed. Ann Rheum Dis 2005; 63: 508-16
37. Weinblatt M. Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of RA in patients taking concomitant MTX. Arthritis Rheum 2003; 48 (1): 35-45
38. Felson D, Anderson J, Meenen R. Use of short-term efficacy/toxicity tradeoffs to select second-line drugs in rheumatoid arthritis: a meta-analysis of published clinical trials. Arthritis Rheum 1992; 35: 1117-25
39. Wolfe F. The mortality of rheumatoid arthritis. Arthritis Rheum 1994; 37 (4): 481-94
40. Young A, Dixey J, Kulinskaya E, et al. Which patients stop working because of rheumatoid arthritis? Results of five years' follow up in 732 patients from the Early RA Study (ERAS). Ann Rheum Dis 2002; 61: 335-40
41. Employment and earnings report, January 2005. Washington, DC: Bureau of Labor Statistics, 2005 Sep 21 [online]. Available from URL: http://www.bls.gov/ ncs/ect/home.htm [Accessed 2006 Sep 6]
42. Yelin E, Trupin L, Katz P, et al. Association between etanercept use and employment outcomes among patients with rheumatoid arthritis. Arthritis Rheum 2003; 48 (11): 3046-54
43. Brennan A, Bansback N, Reynolds A, et al. Modelling the cost-effectiveness of etanercept in adults with rheumatoid arthritis in the UK. Rheumatology 2004; 42: 62-72
44. Bansback NJ, Regier DA, Ara R, et al. An overview of economic evaluations for drugs used in rheumatoid arthritis. Drugs 2005; 65 (4): 473-96
45. Viller F, Guillemin F. Compliance to drug treatment of patients with rheumatoid arthritis: a 3-year longitudinal study. J Rheumatol 1999; 26: 2114-22
46. Ollendorf DA, Massarotti E, Birbara C, et al. Frequency, predictors, and economic impact of upward dose adjustment of infliximab in managed care patients with rheumatoid arthritis. J Manag Care Pharm 2005; 11 (5): 383-93
47. Wolfe F, Michaud K, Anderson J, et al. Tuberculosis infection in patients with rheumatoid arthritis and the effect of infliximab therapy. Arthritis Rheum 2004; 50 (2): 372-9
48. Gabriel S, Crowson C, Luthra H, et al. Modeling the lifetime costs of rheumatoid arthritis. J Rheumatol 1999; 26: 1269-74
49. Wolfe F, Zwillich S. Long-term outcomes of rheumatoid arthritis: a 23-year prospective, longitudinal study of total joint replacement and its predictors in 1600 patients with rheumatoid arthritis. Arthritis Rheum 1998; 41 (6): 1072-82
50. van Vollenhoven R. Switching between biological agents. Clin Exp Rheumatol 2004; 22 Suppl. 35: S115-21
51. Wong J, Singh G, Kavanaugh A. Estimating the cost-effectiveness of 54 weeks of infliximab for rheumatoid arthritis. Am J Med 2002; 113 (5): 400-8